Latest Breaking News On - Company contract research organization - Page 1 : comparemela.com

TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials

TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomBryan kobelCompany contract research organizationTc biopharm holdingsPrnewswire tc biopharm holdings plcContract research organization

TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials

/PRNewswire/ TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform.

United kingdomCity ofBryan kobelPrnewswire tc biopharm holdings plcCompany contract research organizationTc biopharm holdingsContract research organization

Canadian Government Agency Removes Barrier for Psilocybin Therapy

In other industry news of note: Mydecine Innovations Group (CSE:MYCO) (MYCO.CNQ), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, recently announced that it has partnered with ProPharma Group, the leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries. As part of the agreement, ProPharma Group will provide regulatory advisement as the company seeks approval from the Food and Drug Administration (FDA) for its drug development platform as well as the Company s various stage clinical trials. ProPharma Group is a globally recognized firm with a strong track record of working with life sciences and biopharma companies to ensure full compliance with all FDA regulations, including all necessary steps for eventual global federal approvals, said Josh Bartch, CEO and Co-Founder of Mydecine. Mydecine cur

Ben nikolaevskyJosh bartchDevon christieEntheon biomedical corpFn media groupMindspace psychology services incHealth canada office of controlled substancesCentre for human drug researchMydecine innovations groupPropharma groupReed research groupCompany contract research organizationAccess programmePrnewswire health canadaNuminus wellness incTherapeutics ltd

Financial News Media | Canadian Government Agency Removes Barrier for Psilocybin Therapy

Palm Beach, FL – December 16, 2020 – Health Canada, in a recent “breakthrough Exemption” has quietly expanded its list of who can legally possess and consume psilocybin-containing mushrooms by granting 16 health-care professionals the same exemptions it gave more than a dozen patients with terminal and mental illnesses, according to TheraPsil, a Victoria non-profit that has been behind the struggle to treat a list of mental health issues, including debilitating depression, PTSD and even terminal cancer patients. Psilocybin is currently being studied for its potential to treat various conditions such as anxiety, depression, obsessive compulsive disorder and problematic drug use. It is important to note that studies involving the use of Psilocybin require administration of the purified active ingredient in clinically supervised settings. As of right now, there are no approved therapeutic products containing Psilocybin in Canada. Active companies in news today include

Ben nikolaevskyJosh bartchDevon christieEntheon biomedical corpFn media groupMindspace psychology services incHealth canada office of controlled substancesCentre for human drug researchMydecine innovations groupPropharma groupReed research groupCompany contract research organizationAccess programmeNuminus wellness incTherapeutics ltdDrug administration

Baystreet ca - Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs - Completion of Initial DMT Research Drug Batch and Exercise of Warrants Vancouver Canada based Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement with Psygen Labs Inc. Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug substances (“ DMT”) for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the European Medicines Agency (EMA) regulatory framework. On November 27, 2020, Psygen successfully completed the production of a non-GMP DMT research batch for delivery to the Company’s Contract Research Organization, CHDR’s partner pharmacy. The non-GMP DMT research batch will be shipped to CHDR upon receipt of Psygen’s export perm

United statesTimothy koDanny motykaJoseph cullenUniversity of albertaEntheon biomedical corpPsygen labs incMedicine incHealth canada office of controlled substancesCentre for human drug researchEuropean unionStifel nicolaus canada incCompany contract research organizationNuminus wellness incResearch drug batchCanaccord genuity corp